10-Q: Insmed Q3 2025: BRINSUPRI Launch Drives Revenue Growth

Insmed Incorporated reports significant revenue growth in Q3 2025, driven by the US launch of BRINSUPRI and continued ARIKAYCE sales, despite increased operating losses due to substantial R&D and commercialization investments.

Summary

• Product revenues, net, for the three months ended September 30, 2025, increased by $48.9 million (52.4%) to $142.3 million compared to the same period in the prior year.
• This revenue growth was primarily driven by $28.1 million in US commercial sales of BRINSUPRI, following its FDA approval in August 2025, and a 22.3% global growth in ARIKAYCE sales.
• Net loss for Q3 2025 widened to $(370.0) million, compared to $(220.5) million for Q3 2024.
• For the nine months ended September 30, 2025, net loss was $(948.3) million, up from $(678.2) million for the same period in 2024.
• Operating expenses saw significant increases, with Research and Development (R&D) up 23.6% to $186.4 million and Selling, General and Administrative (SG&A) up 56.7% to $186.4 million in Q3 2025, largely due to BRINSUPRI commercialization and ongoing R&D.
• The change in fair value of deferred and contingent consideration liabilities increased by $90.0 million to $104.7 million in Q3 2025, mainly due to an increase in the company's share price.
• Cash and cash equivalents stood at $334.8 million, and marketable securities at $1,345.2 million as of September 30, 2025.
• The company anticipates reporting topline data from the ENCORE trial (ARIKAYCE) in H1 2026, the BiRCh trial (brensocatib for CRSsNP) by early January 2026, and the CEDAR trial (brensocatib for HS) in H1 2026.
• Positive topline results were announced in June 2025 for the Phase 2b study of TPIP in Pulmonary Arterial Hypertension (PAH), with a Phase 3 study planned for early 2026.
• IND clearance was received for INS1202, an intrathecally-delivered gene therapy for Amyotrophic Lateral Sclerosis (ALS), in Q3 2025.

Sentiment

Score: 6

Explanation: The company shows strong commercial growth with a new product launch and existing product expansion, coupled with promising pipeline advancements. However, this is tempered by significant and increasing operating losses, a growing accumulated deficit, and substantial cash burn from operations, indicating ongoing financial challenges and the potential need for future capital raises.

Positives

• Strong product revenue growth: Q3 2025 net product revenues increased 52.4% year-over-year to $142.3 million.
• Successful US launch of BRINSUPRI: Generated $28.1 million in sales in Q3 2025 following FDA approval in August 2025.
• ARIKAYCE sales growth: Global ARIKAYCE sales grew 22.3% in Q3 2025, with international sales up 51.8%.
• Positive regulatory progress for BRINSUPRI: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval in Europe in October 2025, with commercial launches anticipated in 2026 in EU, UK, and Japan.
• Positive Phase 2b results for TPIP in PAH: The study met its primary endpoint with a 35% reduction in pulmonary vascular resistance (PVR) and secondary efficacy endpoints, including a 35.5-meter improvement in 6-minute walk distance (6MWD).
• Advancement of gene therapy pipeline: Investigational New Drug (IND) clearance for INS1202 (ALS) received in Q3 2025, and Phase 1 ASCEND trial initiated for INS1201 (DMD).
• Sufficient liquidity: Cash and cash equivalents of $334.8 million and marketable securities of $1,345.2 million as of September 30, 2025, are expected to fund operations for at least the next 12 months.
• FDA alignment on ENCORE trial primary endpoint for ARIKAYCE, potentially supporting label expansion and full approval for MAC lung disease.

Negatives

• Increased net loss: Net loss for Q3 2025 widened to $(370.0) million from $(220.5) million in Q3 2024, and to $(948.3) million for the nine months ended September 30, 2025, from $(678.2) million in the prior year period.
• Accumulated deficit: The accumulated deficit reached $5.3 billion as of September 30, 2025.
• Substantial operating losses: The company expects to continue incurring consolidated operating losses.
• Significant increase in operating expenses: R&D expenses increased 23.6% to $186.4 million in Q3 2025, and SG&A expenses increased 56.7% to $186.4 million in Q3 2025, contributing to the increased losses.
• Large increase in contingent consideration liability: The change in fair value of deferred and contingent consideration liabilities increased $90.0 million in Q3 2025, primarily due to a rise in the company's share price, indicating higher future payout obligations.
• Increased cash used in operating activities: Net cash used in operating activities increased to $(687.4) million for the nine months ended September 30, 2025, from $(487.9) million for the same period in 2024.

Risks

• Failure to continue to successfully commercialize ARIKAYCE or BRINSUPRI, or failure to maintain US, European, or Japanese approval for ARIKAYCE or US approval for BRINSUPRI.
• Inability to obtain full approval of ARIKAYCE from the FDA, including the risk of not successfully or timely completing the confirmatory post-marketing clinical trial (ENCORE).
• Failure to obtain, or delays in obtaining, regulatory approvals for product candidates (e.g., brensocatib in Europe or Japan, TPIP, gene therapies) or for ARIKAYCE/BRINSUPRI in additional markets.
• Uncertainties or changes in the degree of market acceptance of marketed products or, if approved, product candidates, by physicians, patients, third-party payors, and others in the healthcare community.
• Inability to obtain and maintain adequate reimbursement from government or third-party payors for marketed products or, if approved, product candidates, or acceptable prices for these products.
• Inaccuracies in estimates of the size of potential markets, expected rates of patient uptake, duration of treatment, or patient adherence/discontinuation rates.
• Failure of third parties on which the company is dependent to manufacture sufficient quantities of products for commercial or clinical needs, to conduct clinical trials, or to comply with agreements or regulations.
• Risks and uncertainties associated with the senior secured loan with Pharmakon and royalty financing with OrbiMed, including maintaining compliance with covenants and the impact of operational restrictions.
• Inability to create or maintain an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure.
• Failure to successfully conduct future clinical trials for marketed products or product candidates, and potential inability to enroll or retain sufficient patients.
• Development of unexpected safety or efficacy concerns related to marketed products or product candidates.
• Risks that clinical studies will be delayed, that serious side effects will be identified during drug development, or that any protocol amendments submitted will be rejected.
• Failure to successfully predict the time and cost of development, regulatory approval, and commercialization for novel gene therapy products.
• Risk that interim, topline, or preliminary data from clinical trials may change as more patient data become available or may be interpreted differently.
• Risk that competitors may obtain orphan drug exclusivity for a product essentially the same as one being developed.
• Inability to attract and retain key personnel or to effectively manage growth.
• Inability to successfully integrate acquisitions and appropriately manage management's time and attention devoted to integration activities.
• Risks that acquired technologies, products, and product candidates will not be commercially successful.
• Inability to adapt to a highly competitive and changing environment.
• Inability to access, upgrade, or expand technology systems or difficulties in updating existing technology or developing/implementing new technology.
• Risk of being unable to maintain significant customers.
• Risk that government healthcare reform (e.g., Inflation Reduction Act) materially increases costs and damages financial condition, including potential price negotiation for BRINSUPRI.
• Business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises.
• Risk that current and potential future use of artificial intelligence (AI) and machine learning may not be successful.
• Deterioration in general economic conditions in the US, Europe, Japan, and globally, including the effect of prolonged periods of inflation.
• Risk of becoming involved in costly intellectual property disputes, inability to adequately protect intellectual property rights, or prevent disclosure of trade secrets.
• Restrictions or other obligations imposed by agreements related to marketed products or product candidates, including license agreements with PARI and AstraZeneca.
• The cost and potential reputational damage resulting from litigation, including product liability claims.
• Risk that operations are subject to a material disruption in the event of a cybersecurity attack or issue.
• Limited experience operating internationally and risks associated with international activities and operations.
• Changes in laws and regulations applicable to the business, including any pricing reform and laws that impact the ability to utilize certain third parties.
• History of operating losses and the possibility that profitability may never be achieved or maintained.
• Goodwill impairment charges affecting results of operations and financial condition.
• Inability to repay existing indebtedness and uncertainties with respect to the ability to access future capital.
• Delays in the execution of plans to build out an additional third-party manufacturing facility approved by appropriate regulatory authorities and unexpected expenses associated with those plans.

Future Outlook

The company anticipates reporting topline data from the ARIKAYCE ENCORE trial in the first half of 2026, with a US supplementary NDA submission projected for the second half of 2026. Commercial launches for BRINSUPRI in the EU, UK, and Japan are expected in 2026, pending approval. Topline data for brensocatib in CRSsNP (BiRCh trial) is expected by early January 2026, and for brensocatib in HS (CEDAR trial) in the first half of 2026. A Phase 3 study of TPIP in PH-ILD is expected to initiate in Q4 2025, and a Phase 3 study in PAH in early 2026, with additional Phase 3 studies for TPIP in PPF and IPF anticipated in H2 2026. The company expects to continue incurring substantial operating losses and significant R&D and SG&A expenses in 2025 and beyond, driven by ongoing clinical trials and commercialization efforts. While current funds are sufficient for at least the next 12 months, future cash requirements are substantial, and additional capital may be raised opportunistically. The recently enacted H.R.1 One Big Beautiful Bill is not expected to significantly impact near-term financial position due to net operating losses, and Pillar Two legislation is not anticipated to be effective until global revenues exceed the 750 million Euro threshold.

Management Comments

• We are a people-first global biopharmaceutical company striving to deliver firstand best-in-class therapies to transform the lives of patients facing serious diseases.
• Although it is difficult to predict our future funding requirements, based upon our current operating plan, we anticipate that our cash and cash equivalents and marketable securities as of September 30, 2025 will enable us to fund our operations for at least the next 12 months.
• Our ability to reduce our operating loss and begin to generate positive cash flow from operations depends on the continued success in commercializing our marketed products and achieving positive results from the ARIKAYCE confirmatory clinical trial program in order to obtain full approval of ARIKAYCE in the US and potentially reach more patients.
• Our continued success also depends on successfully commercializing BRINSUPRI, obtaining regulatory approval for brensocatib in additional indications, bringing additional clinical stage products to market, such as TPIP and INS1201, and advancement of our pre-clinical research programs, including INS1202.
• We expect to continue to incur substantial expenses related to our research and development activities... and commercial activities as we launch BRINSUPRI for patients with bronchiectasis.
• We may opportunistically raise additional capital and may do so through equity or debt financing(s), strategic transactions or otherwise.
• We strive to develop and commercialize firstand best-in-class therapies that serve patient communities where the need is greatest.
• We believe that ARIKAYCE has the potential to prove beneficial in other patients with refractory MAC lung disease.
• We believe TPIP may offer a differentiated product profile for PH-ILD and PAH.
• We plan to continue to develop, acquire, in-license or co-promote other products, product candidates and technologies, including those that address serious diseases that currently have significant unmet needs.
• Management does not expect that the ultimate costs to resolve these matters [legal proceedings] will have a material adverse effect on our consolidated financial position, results of operations or cash flows.

Industry Context

Insmed's focus on rare and serious diseases, such as MAC lung disease, non-cystic fibrosis bronchiectasis, Duchenne muscular dystrophy, ALS, and pulmonary hypertension, aligns with a broader biopharmaceutical industry trend towards developing orphan drugs and specialized therapies. These areas often benefit from expedited regulatory pathways and extended market exclusivities, as seen with ARIKAYCE's QIDP and orphan drug designations. The successful US launch of BRINSUPRI and positive clinical data for TPIP position Insmed to expand its market presence in respiratory and rare disease segments. The company's investments in gene therapy and AI-driven protein engineering reflect the industry's shift towards advanced therapeutic modalities. However, the mention of the Inflation Reduction Act (IRA) and Pillar Two legislation highlights the increasing global regulatory and pricing pressures that pharmaceutical companies face, which could impact future profitability and market access.

Comparison to Industry Standards

• ARIKAYCE is positioned as a first-in-class or best-in-class inhaled therapy for MAC lung disease in North America, Europe, and Japan, distinguishing it from intravenous amikacin by offering direct lung delivery, prolonged release, and minimized systemic exposure, potentially reducing systemic toxicities.
• BRINSUPRI (brensocatib) received FDA breakthrough therapy designation for NCFB, indicating its potential for substantial improvement over existing therapies, a strong signal of competitive advantage in the industry. Clinical trials (WILLOW and ASPEN) demonstrated statistically significant reductions in pulmonary exacerbation rates (e.g., 21.1% for 10mg brensocatib vs. placebo in ASPEN), which are competitive efficacy outcomes for chronic respiratory conditions.
• TPIP's Phase 2b study in PAH showed strong efficacy with a 35% reduction in PVR and a 35.5-meter improvement in 6MWD. Its once-daily dosing and potential for fewer side effects compared to current inhaled prostanoid therapies (which require 4-9 doses/day) represent a significant differentiation, offering improved patient convenience and compliance, a critical factor for long-term treatment adherence.
• Insmed's intrathecally-delivered gene therapies (INS1201 for DMD, INS1202 for ALS) aim to target skeletal and cardiac muscles at lower doses than intravenous gene therapies for DMD, potentially offering a safety and efficacy advantage in the highly competitive and unmet-need driven field of gene therapy for rare neurological disorders.

Corporate Governance

Legal Proceedings

• The company is a party to various lawsuits, claims, and other legal proceedings that arise in the ordinary course of business.
• Management does not expect that the ultimate costs to resolve these matters will have a material adverse effect on the company's consolidated financial position, results of operations, or cash flows.

Stakeholder Impact

• Shareholders: May experience dilution from past and potential future equity offerings. Share price is influenced by clinical trial results, regulatory approvals, commercial success, and financial performance (losses, cash burn). Increased contingent consideration liabilities tied to share price could impact future obligations.
• Patients: Benefit from the availability of new therapies like BRINSUPRI and potential label expansion for ARIKAYCE. Pipeline advancements (TPIP, gene therapies) offer future treatment options for serious diseases.
• Employees: Benefit from increased headcount, compensation, and stock-based compensation. New inducement grants are available for new hires.
• Third-party Payors: Engage in ongoing discussions and negotiations regarding pricing and reimbursement for ARIKAYCE and BRINSUPRI, facing potential coverage limitations and pressure on drug prices.
• Suppliers/Manufacturers: The company continues to rely on a limited number of third-party contract manufacturing organizations (CMOs) for product manufacturing, creating a dependency.

Next Steps

• Report topline data from the ENCORE trial (ARIKAYCE) in H1 2026.
• Submit a US supplementary NDA for ARIKAYCE in all MAC lung disease patients in H2 2026.
• Anticipate commercial launches for BRINSUPRI in the EU, UK, and Japan in 2026, pending approval.
• Report topline data from the BiRCh trial (brensocatib for CRSsNP) by early January 2026.
• Report topline data from the CEDAR trial (brensocatib for HS) in H1 2026.
• Initiate PALM-ILD, a Phase 3 study of TPIP in PH-ILD, in Q4 2025.
• Initiate a Phase 3 study of TPIP in PAH in early 2026.
• Initiate additional Phase 3 studies of TPIP in PPF and IPF in H2 2026.
• Continue to progress pre-clinical research programs across various technologies and modalities.
• Actively evaluate in-licensing and acquisition opportunities for products, product candidates, and technologies.
• Continue to provide ARIKAYCE to appropriate patients and expand its reliable revenue stream.
• Advance commercial readiness activities to serve significantly more patients facing serious diseases.
• Control spending and prudently deploy capital to support the best return-generating opportunities.

Key Dates

Recommendation

Insmed demonstrates strong commercial momentum with the successful US launch of BRINSUPRI and continued growth in ARIKAYCE sales, indicating effective market penetration and product acceptance. The pipeline shows promising advancements, particularly with positive Phase 2b TPIP data and multiple upcoming clinical readouts. However, these growth drivers are currently overshadowed by substantial and increasing operating losses, a growing accumulated deficit, and significant cash burn from operations. While the company has sufficient liquidity for the near term, the explicit mention of potential future capital raises suggests ongoing dilution risk. A 'Hold' recommendation reflects the balance between the strong product performance and pipeline potential against the backdrop of significant financial losses and the need for continued investment. Investors should monitor the trajectory of operating losses, the success of BRINSUPRI's international launch, and the outcomes of upcoming clinical trials.

Keywords

Biopharmaceutical, ARIKAYCE, BRINSUPRI, Brensocatib, MAC lung disease, Non-cystic fibrosis bronchiectasis, Pulmonary hypertension, Gene therapy, Duchenne muscular dystrophy, Amyotrophic lateral sclerosis, DPP1 inhibitor, Clinical trials, FDA approval, SEC filing, 10-Q, Financial results, R&D, Commercialization, Orphan drug, QIDP, Treprostinil palmitil inhalation powder, AI-driven protein engineering, RNA end-joining, Synthetic rescue